Mahmut Gümüş

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares, Alexander Luft, David Vicente et al. · New England Journal of Medicine · 2018 · 3.6K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Nicoletta Colombo, Coraline Dubot, Domenica Lorusso et al. · New England Journal of Medicine · 2021 · 992 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Thomas Powles, Begoña P. Valderrama, Shilpa Gupta et al. · New England Journal of Medicine · 2024 · 914 citations · Full text

Medicine, Oncology, Pharmacology +14

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko et al. · The Lancet · 2021 · 799 citations

Medicine, Oncology, Pharmacology +13